Description

• Continuum Lyme is a purified extract of Borrelia burgdorferi comprised of outer surface protein A (OspA) and is adjuvanted to elicit a maximal immune response
• Subunit OspA antigen induces protection against disease caused by B. burgdorferi infection

Indications

• Continuum Lyme is a recombinant OspA vaccine for vaccination of healthy puppies and dogs to prevent disease caused by B. burgdorferi infection
• Vaccination with Continuum Lyme is highly effective in reducing the transmission of infective B. burgdorferi from the tick to the dog

Efficacy and Safety

• Prevented clinical signs in 100% of vaccinates in 1-year challenge¹
• Recombinant OspA formulation kills B. burgdorferi in the tick before it can infect the dog
  • Less potential risk of immune-mediated reactions than with whole-cell bacterins^2-4
• May be safely administered to healthy dogs or puppies as young as 4 weeks of age
• Safety studies using multiple vaccinations did not induce any adverse events regardless of Borrelia serological status

Directions for Use

• Aseptically administer 1 mL by the subcutaneous route
• Vaccinate healthy dogs 4 weeks of age or older with two doses 3-4 weeks apart
• Annual revaccination with a single dose is recommended

References:
1. Data on file, Merck Animal Health
2. Keller D, et al. Safety and immunogenicity of a recombinant outer surface protein A Lyme disease vaccine. J Am Med Assoc. 1994;271(22):1764-1768.

3. Lim LCL, et al. Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi. Infect Immunity. 1994;62(7):2825-2833.
4. Wormser, GP. Prospects for a vaccine to prevent Lyme disease in humans. Clin Infect Dis. 1995;21:1267-1274.